BURLINGTON, MA – Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200, a novel subcutaneously administered ADC that delivers a potent glucocorticoid directly to immune cells. The Phase 1 data from healthy participants were presented at EULAR 2026 in London, UK, from June 3-6, 2026.
LFD-200 was well tolerated and demonstrated dose-responsive anti-inflammatory activity with no impact on serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity. This is a significant finding as current glucocorticoid therapies are associated with systemic side effects such as adrenal suppression, weight gain, and increased infection risk. By targeting immune cells directly, LFD-200 aims to achieve local anti-inflammatory effects while minimizing systemic exposure.
Dosing of patients with moderate to severe rheumatoid arthritis in the Phase 1 study is ongoing, with data expected by year-end 2026. If successful, LFD-200 could offer a new treatment option for rheumatoid arthritis patients who require effective anti-inflammatory control without the burden of systemic steroid side effects.
Lifordi Immunotherapeutics is leading the way in leveraging the success of ADCs to develop treatments for autoimmune and inflammatory disorders. The company has applied its novel drug delivery approach to other payloads, including antisense oligonucleotides (ASOs), siRNA, and small molecules. Backed by investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, visit www.lifordi.com.
